- $9.07m
- $2.33m
- $0.07m
Annual income statement for Silo Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.041 | 0 | 0.071 | 0.072 | 0.072 |
Cost of Revenue | |||||
Gross Profit | 0.013 | 0 | 0.066 | 0.066 | 0.066 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.971 | 2.4 | 2.8 | 3.7 | 3.93 |
Operating Profit | -0.93 | -2.4 | -2.73 | -3.63 | -3.86 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.01 | -2.67 | 4.18 | -3.91 | -3.63 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.01 | -2.67 | 4.16 | -3.91 | -3.63 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -1.01 | -3.04 | 3.9 | -3.91 | -3.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.01 | -3.11 | 2.5 | -3.91 | -3.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.1 | -1.92 | 1.43 | -1.71 | -1.18 |